Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients

被引:98
作者
Forthal, DN
Landucci, G
Haubrich, R
Keenan, B
Kuppermann, BD
Tilles, JG
Kaplan, J
机构
[1] Univ Calif Irvine, Dept Med, Div Infect Dis, Irvine, CA 92717 USA
[2] Univ Calif San Diego, Dept Med, Div Infect Dis, San Diego, CA 92103 USA
[3] Univ Calif San Diego, UCSD Treatment Ctr, Data & Biostat Unit, San Diego, CA 92103 USA
[4] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div SIDS STD & TB Lab Res, Atlanta, GA USA
关键词
D O I
10.1086/314988
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The exact immune defects leading to human immunodeficiency virus (HIV)-associated opportunistic infections, malignancies, and death are unknown. In this study, the relationship between survival and 2 immune functions, cytomegalovirus-specific antibody-dependent cellular cytotoxicity (ADCC) and natural killer (NK) activity, was determined by using peripheral blood mononuclear cells from 39 severely immunocompromised patients (median CD4 count, 7), Median follow-up was 414 days; 15 subjects died and 24 remained alive. In a Kaplan-Meier analysis, high baseline ADCC (>median) was associated with improved survival (P = .05). A similar trend was observed for NK activity (P = .1). In a multivariate model controlling for baseline CD4 cell count, HIV RNA, and use of protease inhibitors during follow-up, high ADCC, but not high NK activity, remained significantly associated with a lower risk of death (relative risk, 0.18; 95% confidence interval, 0.05-0.75). ADCC may be an important determinant of disease progression independently of anti-retroviral therapy, CD4 cell count, and HIV RNA.
引用
收藏
页码:1338 / 1341
页数:4
相关论文
共 13 条
[1]   POSITIVE CORRELATION BETWEEN THE NATURAL-KILLER AND GP120 41-SPECIFIC ANTIBODY-DEPENDENT CELLULAR CYTOTOXIC EFFECTOR FUNCTIONS IN HIV-INFECTED INDIVIDUALS [J].
AHMAD, A ;
MENEZES, J .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 (02) :115-119
[2]  
Baum LL, 1996, J IMMUNOL, V157, P2168
[3]   Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease [J].
Cameron, DW ;
Heath-Chiozzi, M ;
Danner, S ;
Cohen, C ;
Kravcik, S ;
Maurath, C ;
Sun, E ;
Henry, D ;
Rode, R ;
Potthoff, A ;
Leonard, J .
LANCET, 1998, 351 (9102) :543-549
[4]  
Haubrich R, 1998, ANTIVIR THER, V3, P33
[5]   Prognosis in HIV-1 infection predicted by the quantity of virus in plasma [J].
Mellors, JW ;
Rinaldo, CR ;
Gupta, P ;
White, RM ;
Todd, JA ;
Kingsley, LA .
SCIENCE, 1996, 272 (5265) :1167-1170
[6]   RELATIONSHIP BETWEEN CD4 LYMPHOCYTE COUNT AND AIDS MORTALITY, 1986-1991 [J].
MILLS, GD ;
JONES, PD .
AIDS, 1993, 7 (10) :1383-1386
[7]   LOGARITHMIC RELATIONSHIP OF THE CD4 COUNT TO SURVIVAL IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
NIGHTINGALE, SD ;
JOCKUSCH, JD ;
HASLUND, I ;
CAL, SX ;
PETERSON, DM ;
LOSS, SD .
ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (11) :1313-1318
[8]   SPONTANEOUS HUMAN LYMPHOCYTE-MEDIATED CYTO-TOXICITY AGAINST TUMOR TARGET-CELLS .9. THE QUANTITATION OF NATURAL-KILLER CELL-ACTIVITY [J].
PROSS, HF ;
BAINES, MG ;
RUBIN, P ;
SHRAGGE, P ;
PATTERSON, MS .
JOURNAL OF CLINICAL IMMUNOLOGY, 1981, 1 (01) :51-63
[9]  
ROOK AH, 1988, REV INFECT DIS S3, V10, P460
[10]   Quantitative HIV-1 RNA as a marker of clinical stability and survival in a cohort of 302 patients with a mean CD4 cell count of 300x10(6)/l [J].
Ruiz, L ;
Romeu, J ;
Clotet, B ;
Balague, M ;
Cabrera, C ;
Sirera, G ;
Ibanez, A ;
Martinez-Picado, J ;
Raventos, A ;
Tural, C ;
Segura, A ;
Foz, M .
AIDS, 1996, 10 (11) :F39-F44